市場調査レポート

北米の顔面注射剤市場

North American Markets for Facial Injectables 2013

発行 Millennium Research Group 商品コード 227377
出版日 ページ情報 英文
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=106.02円で換算しております。
Back to Top
北米の顔面注射剤市場 North American Markets for Facial Injectables 2013
出版日: 2012年11月16日 ページ情報: 英文
概要

ボツリヌス毒素(BTX)や皮膚充填剤製品(ヒアルロン酸、準定着・非定着性の非ヒアルロン酸剤を含む)に代表される顔面注射剤の北米市場は、2008年後半に始まった不況期を通じて大幅な落ち込みを見せたものの、その後順調に回復し、ヒアルロン酸および皮膚充填剤いずれの分野も、2016年までは旺盛な需要に支えられながら、急速かつ安定的な成長が見込まれています。

当レポートでは、こうした北米顔面注射剤市場の実像を探るべく、周到な予備調査から得られた基礎情報に業界関係者の直接取材を積み上げた検証結果をまとめ、概略以下の構成でお届けします。

エグゼクティブサマリー

第1章 国別概要

  • 米国
    • 人口統計と経済
    • 医療制度
    • 規制環境
  • カナダ
    • 人口統計と経済
    • 医療制度
    • 規制環境
    • 製造・流通

第2章 臨床環境

  • 背景
  • 処置概要
    • 競合療法(全8種)
  • ガイドラインと診断パターン

第3章 製品

  • 製品概要
    • ボツリヌス毒素
      • 機能
    • 皮膚充填剤
      • 機能
        • ヒアルロン酸充填剤
        • その他
      • 差別化要因
  • 将来の技術

第4章 治験

  • 完了した治験
  • 進行中の治験

第5章 顔面注射剤市場

  • 市場の現状
  • 市場の詳細分析
  • 競合概要
  • 詳細な競合環境
  • 市場シェア
  • 近年の動向
  • 最も有望な新規製品

第6章 ボツリヌス毒素市場

  • 市場の現状
  • 市場の詳細分析
  • 競合概要
  • 市場シェア

第7章 皮膚充填剤市場

  • 市場の現状
  • 市場の詳細分析
    • ヒアルロン酸充填材
    • その他の充填材
  • 競合概要
  • 市場シェア

付録:分析手法

付録:略語・頭語集

付録:関連分析

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: RPNA41FA12

The North American facial injectable market - comprising revenues from the sale of botulinum toxin (BTX) and dermal filler products, including hyaluronic acid (HA) dermal fillers, and semi- and nonpermanent non-HA fillers - experienced a large decline during the recession, starting in late 2008, but have since experienced a strong recovery. Through 2016, both the BTX and dermal filler markets will experience high growth as patients continue to demand aesthetic procedures. The entry of Merz Pharmaceutical's Belotero and Xeomin (dermal filler and BTX products, respectively) in 2011 is expected to alter the competitive landscape because physicians and patients will have a larger range of products to choose from. Competitive pricing pressures, heightened by Merz Pharmaceutical's entry into the market, will limit market growth. Nevertheless, increasing patient aesthetic consciousness and the resultant demand for facial injectable procedures will drive unit sales, thus facilitating the expansion of both the BTX and dermal filler markets. The US market will continue to account for the majority of facial injectable sales compared to Canada due to a larger overall population and a more aesthetically conscious population. Overall, the North American facial injectable market will experience steady and high growth over the forecast period as the number of patients demanding for the treatments continues to rise.

Companies mentioned in this report:

  • Alcon
  • Allergan
  • Anika Therapeutics
  • Anteis
  • Clarion Medical
  • Coapt Systems
  • Fibrocell Science
  • Ipsen
  • Laboratoires TEOXANE
  • Medicis Pharmaceutical
  • Mentor (a Johnson & Johnson company)
  • Merz Pharmaceuticals
  • Polymekon
  • Prollenium Medical Technologies
  • Q-Med (acquired by Galderma)
  • Revance Therapeutics
  • Rofil Medical International
  • Sanofi
  • Solstice Neurosciences
  • Suneva Medical
  • US WorldMeds
  • Valeant Pharmaceuticals

Table of Contents

TABLE OF CONTENTS

LIST OF FIGURES AND TABLES

EXECUTIVE SUMMARY

1. COUNTRY OVERVIEWS

  • 1.1. US
    • 1.1.1. Demographics and Economy
    • 1.1.2. Health Care System
    • 1.1.3. Regulatory Environment
  • 1.2. Canada
    • 1.2.1. Demographics and Economy
    • 1.2.2. Health Care System
    • 1.2.3. Regulatory Environment
    • 1.2.4. Manufacturing and Distribution

2. CLINICAL LANDSCAPE

  • 2.1. Background
  • 2.2. Procedure Descriptions
    • 2.2.1. Competing Treatments
      • 2.2.1.1. Laser Resurfacing
      • 2.2.1.2. Facial Lifts
      • 2.2.1.3. Chemical Peels
      • 2.2.1.4. Dermabrasion
      • 2.2.1.5. Cosmeceuticals
      • 2.2.1.6. Nutricosmetics
      • 2.2.1.7. Nutrigenomics
      • 2.2.1.8. Emerging Competing Treatments
  • 2.3. Guidelines and Diagnosis Patterns

3. PRODUCTS

  • 3.1. Product Descriptions
    • 3.1.1. Botulinum Toxins
      • 3.1.1.1. Functions
    • 3.1.2. Dermal Fillers
      • 3.1.2.1. Functions
        • 3.1.2.1.1. Hyaluronic Acid Fillers
          • 3.1.2.1.1.1. Standard Hyaluronic Acid Dermal Fillers
          • 3.1.2.1.1.2. Rejuvenation Hyaluronic Acid Dermal Fillers
          • 3.1.2.1.1.3. Volumizing Hyaluronic Acid Dermal Fillers
        • 3.1.2.1.2. Other Dermal Fillers
      • 3.1.2.2. Differentiating Features
  • 3.2. Future Technologies

4. CLINICAL TRIALS

  • 4.1. Completed Clinical Trials
  • 4.2. Ongoing Clinical Trials

5. FACIAL INJECTABLE MARKET

  • 5.1. Market Snapshot
  • 5.2. Detailed Market Analysis
  • 5.3. Competitive Snapshot
  • 5.4. Detailed Competitive Landscape
  • 5.5. Market Shares
  • 5.6. Recent Events
  • 5.7. Most Promising Emerging Products

6. BOTULINUM TOXIN MARKET

  • 6.1. Market Snapshot
  • 6.2. Detailed Market Analysis
  • 6.3. Competitive Snapshot
  • 6.4. Market Shares

7. DERMAL FILLER MARKET

  • 7.1. Market Snapshot
  • 7.2. Detailed Market Analysis
    • 7.2.1. Hyaluronic Acid Dermal Fillers
    • 7.2.2. Other Dermal Fillers
  • 7.3. Competitive Snapshot
  • 7.4. Market Shares

APPENDIX: METHODOLOGY

APPENDIX: ACRONYMS AND INITIALISMS

APPENDIX: BIBLIOGRAPHY

LIST OF FIGURES AND TABLES

TABLE OF CONTENTS

LIST OF FIGURES AND TABLES

EXECUTIVE SUMMARY

  • Figure 1: Facial Injectable Market, by Product Type, North America (USD), 2011 - 2017
  • Table 1: Facial Injectable Market Landscape, North America (USD), 2012 and 2017
  • Table 2: Facial Injectable Market Leaders, by Product Type and Revenue, North America, 2012
  • Table 3: Companies Mentioned
  • Table 4: Factors Impacting the Facial Injectable Market, by Product Type, North America, 2012 - 2017
  • Table 5: Recent Novel Devices in the Facial Injectable Market, by Product Type, North America, 2012
  • Table 6: Expected Key Events in the Facial Injectable Market, North America, 2013 - 2017
  • Table 7: Geographies Covered, North America
  • Table 8: Average Currency Exchange Rates
  • Table 9: Facial Injectable Procedures Covered, North America
  • Table 10: Facial Injectables Products Covered, North America
  • Table 11: Common Facial Injectable Brands

1. COUNTRY OVERVIEWS

  • Table 12: Key Health and Economic Indicators, US
  • Table 13: Key Health and Economic Indicators, Canada

2. CLINICAL LANDSCAPE

  • Table 14: Areas of the Face Commonly Treated with Facial Injectables
  • Table 15: Common Facial Injectable Indications, by Product Type
  • Table 16: Facial Injectable Treatment Guidelines, by Product Type

3. PRODUCTS

  • Table 17: Advantages and Disadvantages of Facial Injectables, by Product Type
  • Table 18: BTX-A and BTX-B Functions
  • Table 19: Dermal Filler Functions, by Material and Product Feature
  • Table 20: Advantages and Disadvantages of Dermal Fillers, by Material and Product Feature

4. CLINICAL TRIALS

  • Table 21: Summary of Head2Head
  • Table 22: Summary of Safety and Efficacy of Two Types of Botulinum Toxin Type A for the Treatment of Glabellar Lines
  • Table 23: Summary of Multicenter Study of the Safety and Effectiveness of Dermal Filler, Belotero
  • Table 24: Summary of Safety and Effectiveness of Aquamid as Compared to Restylane for the Aesthetic Treatment
  • Table 25: Summary of EMERVEL Classic Lidocaine Versus JUVEDERM Ultra in Treatment of Moderate to Severe Facial Wrinkles and Folds
  • Table 26: Summary of Safety and Efficacy of JUVEDERM Injectable Gel with Lidocaine
  • Table 27: Summary of Solid State Hyaluronic Acid: A Novel Delivery System to Enable the Precise and Rapid Treatment of Fine and Deep Wrinkles
  • Table 28: Summary of Post-Market Study of JUVEDERM VOLIFT With Lidocaine for the Correction of Nasolabial Folds
  • Table 29: Summary of JUVE_BTX
  • Table 30: Summary of FIRST
  • Table 31: Summary of Lateral Canthal Rhytides With Medium Depth Chemical Peel With or Without Pretreatment With Botulinum Toxin A
  • Table 32: Summary of Volume Restoration of the Aging Midface with Sculptra Aesthetic
  • Table 33: Summary of Efficacy and Safety Study of Botulinum Toxin Type A to Treat Glabellar Lines
  • Table 34: Summary of Safety and Efficacy Study of Botulinum Toxin Type A to Treat Glabellar Lines
  • Table 35: Summary of Efficacy and Safety Study of Neuramis in Correction of Nasolabial Fold
  • Table 36: Summary of Efficacy and Safety of DWP450 Compared With Botox in Moderate to Severe Glabellar Line

5. FACIAL INJECTABLE MARKET

  • Figure 2: Facial Injectable Market, by Country, North America (USD), 2011 - 2017
  • Table 37: Factors Impacting the Facial Injectable Market, by Product Type, North America, 2012 - 2017
  • Table 38: Volume of Facial Injectable Product per Procedure, by Product Type
  • Table 39: Facial Injectable Procedures, by Product Type, North America, 2011 - 2017
  • Table 40: Facial Injectable Procedures, by Country, North America, 2011 - 2017
  • Table 41: Facial Injectable Procedures, by Anatomy and Country, North America, 2012
  • Table 42: Facial Injectable Market, by Product Type, North America (USD), 2011 - 2017
  • Table 43: Facial Injectable Market Growth, by Product Type, North America, 2012 - 2017
  • Table 44: Facial Injectable Market, by Product Type, as a % of Total, North America, 2011 - 2017
  • Table 45: Facial Injectable Market, by Country, North America (USD and CAD), 2011 - 2017
  • Table 46: Facial Injectable Market Growth, by Country, North America, 2012 - 2017
  • Table 47: Facial Injectable Market, by Country, as a % of Total, North America, 2011 - 2017
  • Figure 3: Leading Competitors in the Facial Injectable Market, as a % of Total, North America, 2012
  • Table 48: Leading Competitors in the Facial Injectable Market, by Product Type, as a % of Total, North America, 2012
  • Table 49: Leading Competitors in the Facial Injectable Market, by Country, as a % of Total, North America, 2012
  • Table 50: Recent Events in the Facial Injectable Market, North America
  • Table 51: Emerging Products in Development for the Facial Injectable Market, North America, 2012 - 2017

6. BOTULINUM TOXIN MARKET

  • Figure 4: BTX Market, by Country, North America (USD), 2011 - 2017
  • Table 52: BTX Procedures, by Country, North America, 2011 - 2017
  • Table 53: BTX Procedures, by Anatomy and Country, North America, 2012
  • Table 54: BTX Market, by Country, North America (USD and CAD), 2011 - 2017
  • Table 55: BTX Market Growth, by Country, North America, 2012 - 2017
  • Table 56: BTX Market, by Country, as a % of Total, North America, 2011 - 2017
  • Figure 5: Leading Competitors in the BTX Market, as a % of Total, North America, 2012
  • Table 57: Leading Competitors in the BTX Market, by Country, as a % of Total, North America, 2012

7. DERMAL FILLER MARKET

  • Figure 6: Dermal Filler Market, by Country, North America (USD), 2011 - 2017
  • Table 58: Dermal Filler Procedures, by Material, North America, 2011 - 2017
  • Table 59: Dermal Filler Procedures, by Country, North America, 2011 - 2017
  • Table 60: Dermal Filler Procedures, by Anatomy and Country, North America, 2012
  • Table 61: Dermal Filler Market, by Material, North America (USD), 2011 - 2017
  • Table 62: Dermal Filler Market Growth, by Material, North America, 2012 - 2017
  • Table 63: Dermal Filler Market, by Material, as a % of Total, North America, 2011 - 2017
  • Table 64: Dermal Filler Market, by Country, North America (USD and CAD), 2011 - 2017
  • Table 65: Dermal Filler Market Growth, by Country, North America, 2012 - 2017
  • Table 66: Dermal Filler Market, by Country, as a % of Total, North America, 2011 - 2017
  • Table 67: HA Dermal Filler Procedures, by Country, North America, 2011 - 2017
  • Table 68: HA Dermal Filler Procedures, by Anatomy and Country, North America, 2012
  • Table 69: HA Dermal Filler Market, by Country, North America (USD and CAD), 2011 - 2017
  • Table 70: HA Dermal Filler Market Growth, by Country, North America, 2012 - 2017
  • Table 71: HA Dermal Filler Market, by Country, as a % of Total, North America, 2011 - 2017
  • Table 72: Other Dermal Filler Procedures, by Country, North America, 2011 - 2017
  • Table 73: Other Dermal Filler Procedures, by Anatomy and Country, North America, 2012
  • Table 74: Other Dermal Filler Market, by Country, North America (USD and CAD), 2011 - 2017
  • Table 75: Other Dermal Filler Market Growth, by Country, North America, 2012 - 2017
  • Table 76: Other Dermal Filler Market, by Country, as a % of Total, North America, 2011 - 2017
  • Figure 7: Leading Competitors in the Dermal Filler Market, as a % of Total, North America, 2012
  • Table 77: Leading Competitors in the Dermal Filler Market, by Material, as a % of Total, North America, 2012
  • Table 78: Leading Competitors in the Dermal Filler Market, by Country, as a % of Total, North America, 2012
  • Table 79: Leading Competitors in the HA Dermal Filler Market, by Country, as a % of Total, North America, 2012
  • Table 80: Leading Competitors in the Other Dermal Filler Market, by Country, as a % of Total, North America, 2012

APPENDIX: METHODOLOGY

APPENDIX: ACRONYMS AND INITIALISMS

  • Table 81: Acronyms and Initialisms

APPENDIX: BIBLIOGRAPHY

Back to Top